Krystal Biotech Inc.(KRYS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KRYS Krystal Biotech Inc.

Post-Mkt 07-02 19:59:46 EDT

375.07

+3.49

+0.94%

盘后378.28

+3.20+0.85%

19:38 EDT

High377.35	Low365.28	Vol235.28K
Open374.57	D1 Closing371.58	Amplitude3.25%
Mkt Cap11.04B	Tradable Cap8.62B	Total Shares29.44M
T/O87.48M	T/O Rate1.02%	Tradable Shares22.98M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"KRYS","market":"US","secType":"STK","nameCN":"Krystal Biotech Inc.","latestPrice":375.07,"timestamp":1783022400000,"preClose":371.58,"halted":0,"volume":235279,"hourTrading":{"tag":"盘后","latestPrice":378.275,"preClose":375.07,"latestTime":"19:38 EDT","volume":4829,"amount":1811479.7839600001,"timestamp":1783035521122,"change":3.205,"changeRate":0.008545,"amplitude":0.039806},"delay":0,"changeRate":0.009392324667635527,"floatShares":22979893,"shares":29435746,"eps":7.47,"marketStatus":"Post-Mkt","change":3.49,"latestTime":"07-02 19:59:46 EDT","open":374.57,"high":377.35,"low":365.28,"amount":87475645.21102001,"amplitude":0.032483,"askPrice":415.2,"askSize":40,"bidPrice":322.74,"bidSize":1,"shortable":3,"etf":0,"ttmEps":7.47,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1783036800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1505880000000,"exchange":"NASDAQ","adjPreClose":371.58,"preHourTrading":{"tag":"盘前","latestPrice":373,"preClose":371.58,"latestTime":"09:03 EDT","volume":52,"amount":19650.41104,"timestamp":1782997436217,"change":1.42,"changeRate":0.003822,"amplitude":0.018758},"postHourTrading":{"tag":"盘后","latestPrice":378.275,"preClose":375.07,"latestTime":"19:38 EDT","volume":4829,"amount":1811479.7839600001,"timestamp":1783035521122,"change":3.205,"changeRate":0.008545,"amplitude":0.039806},"volumeRatio":0.464788,"impliedVol":0.4563,"impliedVolPercentile":0.5498},"requestUrl":"/m/hq/s/KRYS","defaultTab":"news","newsList":[{"id":"2646395807","title":"Krystal Biotech EVP, General Counsel John C. Thomas Disposes of USD 347,270 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2646395807","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646395807?lang=en_us&edition=fundamental","pubTime":"2026-06-27 06:46","pubTimestamp":1782513993,"startTime":"0","endTime":"0","summary":"Krystal Biotech EVP, General Counsel John C. Thomas disposes of USD 347,270 in common sharesKrystal Biotech EVP, General Counsel Thomas John Charles exercised options for 1,000 shares at USD 179.25 on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDL6xTVkt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Krystal Biotech EVP, General Counsel John C. Thomas Disposes of USD 347,270 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645727800","title":"Krystal Biotech (KRYS) Is Up 7.2% After Institutional Ownership Surges To Sector-Leading Levels","url":"https://stock-news.laohu8.com/highlight/detail?id=2645727800","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645727800?lang=en_us&edition=fundamental","pubTime":"2026-06-23 02:27","pubTimestamp":1782152852,"startTime":"0","endTime":"0","summary":"In recent months, Krystal Biotech has seen its institutional shareholding score reach the maximum of 10.00, with major investors such as ETHSX and BlackRock increasing their positions and lifting overall institutional ownership by 11.17% quarter-over-quarter.\nThis sharp rise in institutional participation places Krystal Biotech at the top of its Biotechnology & Medical Research peer group for institutional backing, highlighting stronger professional investor interest despite limited...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/krystal-biotech-krys-is-up-72-after-institutional-ownership","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/krystal-biotech-krys-is-up-72-after-institutional-ownership","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","BK4588","XBI","BK4581","BK4139","KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643757755","title":"Krystal Biotech, Inc. : H.c. Wainwright Raises Target Price to $361 From $310","url":"https://stock-news.laohu8.com/highlight/detail?id=2643757755","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643757755?lang=en_us&edition=fundamental","pubTime":"2026-06-16 21:01","pubTimestamp":1781614907,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nAZN4T2KM4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643773247","title":"U.S. RESEARCH ROUNDUP-CAMP4 Therapeutics, Rockwell Automation, Zions Bancorporation","url":"https://stock-news.laohu8.com/highlight/detail?id=2643773247","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643773247?lang=en_us&edition=fundamental","pubTime":"2026-06-16 16:11","pubTimestamp":1781597519,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-CAMP4 Therapeutics, Rockwell Automation, Zions BancorporationJune 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed co","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nL8N42O0EI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4159","IE0002141913.USD","FICO","COHU","XOMO","EXR","FAST","FLUT","INSM","LU0029874061.USD","XOM","AIT","XOMX","ESAB","BDC","HBAN","BK4533","EMR","CAMP","FITB","KRC","EFX","DOMO","PLAY","BBIO","GPC","KMX","FOXA","ZION","CVLT","HWM","KEY","KRYS","LU1150488218.USD","AMGN","DT","KMT","LEN","ROKU","HPP","CCL","MSM","ELF","FCEL","CFG","XOMZ","AKTS","BK4147","CSR","BETR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641233371","title":"Krystal Biotech CEO Krish S. Krishnan sells USD 7.77 million in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2641233371","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641233371?lang=en_us&edition=fundamental","pubTime":"2026-06-06 06:39","pubTimestamp":1780699156,"startTime":"0","endTime":"0","summary":"Krystal Biotech President and CEO Krish S. Krishnan sold 25,000 common shares on June 4.Sales priced from USD 300.75 to USD 312.23 per share.Directly held stake fell to 1,450,253 shares following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Krystal Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nNDLbD5Mht:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Krystal Biotech CEO Krish S. Krishnan sells USD 7.77 million in common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640156650","title":"A Look At Krystal Biotech (KRYS) Valuation After Vyjuvek Driven Earnings Beat And Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2640156650","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640156650?lang=en_us&edition=fundamental","pubTime":"2026-06-04 17:36","pubTimestamp":1780565793,"startTime":"0","endTime":"0","summary":"Krystal Biotech (KRYS) shares moved after the company reported first quarter 2026 results, with earnings per share above estimates and revenue growth tied to strong Vyjuvek uptake, and reaffirmed expense guidance.\nSee our latest analysis for Krystal Biotech.\nThe stock has built solid momentum over the past year, with a 1-year total shareholder return of 128.6% and a year to date share price return of 22.24%. The latest 1-day move of 2.94% after earnings suggests investors are reassessing...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/a-look-at-krystal-biotech-krys-valuation-after-vyjuvek-drive","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/a-look-at-krystal-biotech-krys-valuation-after-vyjuvek-drive","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["KRYS","PRGS","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640953709","title":"H.C. Wainwright Sticks to Their Buy Rating for Krystal Biotech (KRYS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640953709","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640953709?lang=en_us&edition=fundamental","pubTime":"2026-06-01 18:36","pubTimestamp":1780310211,"startTime":"0","endTime":"0","summary":"In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Krystal Biotech, with a price target of $310.00. Accor...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-krystal-biotech-krys-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-krystal-biotech-krys-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KRYS","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640849739","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Krystal Biotech (KRYS), AbbVie (ABBV) and Tempus AI, Inc. Class A (TEM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640849739","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640849739?lang=en_us&edition=fundamental","pubTime":"2026-06-01 09:20","pubTimestamp":1780276807,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Krystal Biotech (KRYS), AbbVie (ABBV) and Tempus A...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-krystal-biotech-krys-abbvie-abbv-and-tempus-ai-inc-class-a-tem-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-krystal-biotech-krys-abbvie-abbv-and-tempus-ai-inc-class-a-tem-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0310800379.SGD","LU0234572021.USD","LU0234570918.USD","LU1023059063.AUD","LU1037948897.HKD","IE00BSNM7G36.USD","LU0069063385.USD","LU1244550221.USD","LU1267930490.SGD","LU0256863811.USD","IE0000B7K699.USD","LU0882574055.USD","LU1934455277.USD","LU1244550494.USD","LU1989771016.USD","LU2087621335.USD","SG9999011175.SGD","IE000BZT7R73.USD","LU1718418525.SGD","IE000MB6IJN5.SGD","IE00B19Z3581.USD","LU1003077747.HKD","LU0128525929.USD","LU0472753341.HKD","LU1934455863.HKD","LU0203345920.USD","LU2237443549.SGD","LU0456855351.SGD","LU1551013425.SGD","LU1861558580.USD","LU0289739699.SGD","LU0795875169.SGD","LU1670628061.USD","LU0158827948.USD","LU1496350502.SGD","LU2468319806.SGD","LU1074936037.SGD","LU0029864427.USD","LU0689472784.USD","LU2089284900.SGD","IE00BVYPNW00.USD","LU0942090050.USD","LU2023251221.USD","IE00B19Z3B42.SGD","LU0965509283.SGD","LU2347655156.SGD","BK4121","LU2237443895.HKD","LU1732800096.USD","IE00B42XCP33.USD","IE00BLSP4452.SGD","BK4559","LU0868494708.USD","ABBV","IE000F7OJYX1.SGD","IE00BN8TJ469.HKD","LU1162221912.USD","LU0868494617.USD","BK4550","BK4581","LU0114720955.EUR","LU1670627923.USD","LU1983299246.USD","SG9999015986.USD","LU2357627491.SGD","LU0198837287.USD","LU0310799852.SGD","BK4139","BK4588","LU1934455194.USD","BK4613","IE0004445239.USD","LU2237443465.HKD","LU0170899867.USD","LU1496350171.SGD","BK4533","LU0823416689.USD","LU2089283258.USD","LU1929549753.HKD","KRYS","LU0965509101.SGD","LU1244550577.SGD","IE00BVYPNV92.GBP","LU0859254822.USD","TEM","LU0553294199.USD","LU2237443978.SGD","SG9999015952.SGD","IE00BDGV0183.EUR","IE00BJJMRZ35.SGD","LU0965509010.AUD","LU0708994859.HKD","LU1430594728.SGD","LU0943347566.SGD","LU0057025933.USD","LU0820561909.HKD","LU0985320562.USD","LU1057294990.SGD","LU0912757837.SGD","IE00B2B36J28.USD","IE0002270589.USD","IE00BBT3K403.USD","LU0122379950.USD","LU2237443622.USD","LU0432979614.USD","LU1291159041.SGD","LU1551013342.USD","LU2089984988.USD","LU0965508806.USD","LU0511384066.AUD","LU2133065610.SGD","LU0738911758.USD","LU0211327993.USD","LU0545039389.USD","IE00BFTCPJ56.SGD","LU0795875086.SGD","LU0689626769.HKD","SG9999015978.USD","BK4566","LU0417517546.SGD","TEMT","LU0211328371.USD","IE00BJT1NW94.SGD","LU0203347892.USD","SG9999003800.SGD","LU1093756168.USD","LU0820561818.USD","LU1037948541.HKD","LU0661504455.SGD","LU2112291526.USD","BK4534","SG9999001440.SGD","LU1061106388.HKD","LU1093756325.SGD","LU2129689605.HKD","LU2237443382.USD","LU0861579265.USD","LU0289739343.SGD","IE0009355771.USD","LU0256863902.USD","LU1267930573.SGD","LU1861559042.SGD","LU1585245621.USD","IE00B3PB1722.GBP","LU1839511570.USD","IE00B4R5TH58.HKD","LU0289961442.SGD","LU0098860793.USD","LU1989772840.SGD","IE000SO60NU8.SGD","LU2129689431.USD","IE00BGHQF631.EUR","SG9999015945.SGD","IE000WAW04H5.SGD","LU0124676726.USD","LU0058720904.USD","LU1732799900.SGD","LU1989772923.USD","LU2129689514.USD","IE00BLSP4239.USD","IE0002141913.USD","LU0320765646.SGD","BK4585","BK4611","LU0949170772.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638695080","title":"Exploring High Growth Tech Stocks In The US Market May 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2638695080","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638695080?lang=en_us&edition=fundamental","pubTime":"2026-05-28 19:08","pubTimestamp":1779966493,"startTime":"0","endTime":"0","summary":"The United States market has shown robust performance, rising 1.3% over the last week and 28% over the past year, with earnings projected to grow by 17% annually. In this thriving environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and scalability potential to capitalize on these favorable conditions.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/exploring-high-growth-tech-stocks-in-the-us-market-may-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/exploring-high-growth-tech-stocks-in-the-us-market-may-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["KRYS","XBI","FIVN","BK4023","BK4585","BK4588","AVXL","BK4139","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638397246","title":"Krystal Biotech EVP, General Counsel John C. Thomas sells 642 shares for $193,903.26","url":"https://stock-news.laohu8.com/highlight/detail?id=2638397246","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638397246?lang=en_us&edition=fundamental","pubTime":"2026-05-28 05:18","pubTimestamp":1779916714,"startTime":"0","endTime":"0","summary":"Krystal Biotech EVP, General Counsel Thomas John Charles sold 642 common shares on May 26, 2026.Shares sold at USD 302.03 each; post-transaction beneficial ownership reported as 0 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Krystal Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 27, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL2NqsrB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Krystal Biotech EVP, General Counsel John C. Thomas sells 642 shares for $193,903.26","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638230130","title":"A Look At Krystal Biotech (KRYS) Valuation After UK Approval And Exclusivity Win For VYJUVEK","url":"https://stock-news.laohu8.com/highlight/detail?id=2638230130","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638230130?lang=en_us&edition=fundamental","pubTime":"2026-05-25 00:21","pubTimestamp":1779639689,"startTime":"0","endTime":"0","summary":"Krystal Biotech (KRYS) is back in focus after the United Kingdom granted marketing authorization for VYJUVEK, the first genetic medicine approved there for dystrophic epidermolysis bullosa, with orphan status and potential 12-year exclusivity.\nSee our latest analysis for Krystal Biotech.\nAt a latest share price of US$299.45, Krystal Biotech has pulled back over the past week but still shows a 30 day share price return of 9.88% and a 1 year total shareholder return of 139.46% relating to...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/a-look-at-krystal-biotech-krys-valuation-after-uk-approval-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/a-look-at-krystal-biotech-krys-valuation-after-uk-approval-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","KRYS","BK4585","XBI","BK4588","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637162433","title":"Krystal Biotech (KRYS) Gets a Buy from Bank of America Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2637162433","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637162433?lang=en_us&edition=fundamental","pubTime":"2026-05-22 19:16","pubTimestamp":1779448599,"startTime":"0","endTime":"0","summary":"Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Krystal Biotech today and set a price target of $364.00. According to ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/krystal-biotech-krys-gets-a-buy-from-bank-of-america-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/krystal-biotech-krys-gets-a-buy-from-bank-of-america-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","BK4559","LU0477156797.USD","LU2129689605.HKD","LU0234570918.USD","IE00B19Z3B42.SGD","PGF","KRYS","LU0320765646.SGD","LU1267930227.SGD","LU1880398471.USD","LU0477156953.USD","IE00BKVL7J92.USD","LU0980610538.SGD","LU1069347547.HKD","LU0208291251.USD","LU0211331839.USD","LU0256863902.USD","LU0310800965.SGD","LU1894683348.USD","LU1718418525.SGD","LU0128525689.USD","LU2129689514.USD","BAC","LU1162221912.USD","LU1804176565.USD","LU0868494617.USD","IE0001KFT4U8.USD","LU1791807156.HKD","LU0106831901.USD","LU0314106906.USD","LU1201861249.SGD","LU1496350171.SGD","LU0052756011.USD","LU0053666078.USD","LU1366192091.USD","LU1363072403.SGD","BK4553","LU0203345920.USD","LU1668664300.SGD","BK4581","LU0130517989.USD","IE00BLSP4239.USD","LU0130102774.USD","LU0320765489.SGD","LU1880398554.USD","LU0683600562.USD","BK4582","LU1883839398.USD","BK4504"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637477333","title":"Corbus Pharma names Nishant Saxena chief business officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2637477333","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637477333?lang=en_us&edition=fundamental","pubTime":"2026-05-21 20:01","pubTimestamp":1779364875,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals named Nishant Saxena as its first chief business officer as it moves toward registrational-stage development for its lead programs.Saxena was most recently chief financial officer at Jeune Aesthetics, a unit of Krystal Biotech.He previously spent more than 15 years at Evercore, most recently as a managing director in the healthcare group advising on mergers, acquisitions, financings, and partnerships.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corbus Pharmaceuticals Holdings Inc. published the original content used to generate this news brief on May 21, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL9PXsTn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KRYS","BK4127","CRBP","EVR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637333084","title":"Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2637333084","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637333084?lang=en_us&edition=fundamental","pubTime":"2026-05-21 20:00","pubTimestamp":1779364800,"startTime":"0","endTime":"0","summary":"NORWOOD, Mass., May  21, 2026  (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity,","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299267/0/en/Corbus-Pharmaceuticals-Announces-the-Appointment-of-Nishant-Saxena-as-Chief-Business-Officer-and-Schedules-a-Pre-2026-ASCO-CRB-701-Data-Conference-Call.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP","ADC","BK4139","KRYS","BK4231","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636984353","title":"Krystal Biotech shareholders elected Krishnan, Mason as Class III directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2636984353","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636984353?lang=en_us&edition=fundamental","pubTime":"2026-05-20 18:03","pubTimestamp":1779271435,"startTime":"0","endTime":"0","summary":"Krystal Biotech held its annual shareholder meeting on May 15, 2026.Unaffiliated shareholders adopted a non-employee director compensation policy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Krystal Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL9cVcvL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636734760","title":"Krystal Biotech announces UK MHRA approval of Vyjuvek","url":"https://stock-news.laohu8.com/highlight/detail?id=2636734760","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636734760?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:17","pubTimestamp":1779106659,"startTime":"0","endTime":"0","summary":"Krystal Biotech (KRYS) announced that the United Kingdom Medicines and Healthcare products Regulatory Agency, or MHRA, granted marketing authorizat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/krystal-biotech-announces-uk-mhra-approval-of-vyjuvek-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/krystal-biotech-announces-uk-mhra-approval-of-vyjuvek-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4585","XBI","KRYS","LABU","XLV","BK4588","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636738290","title":"Krystal Biotech wins UK MHRA approval for Vyjuvek in dystrophic epidermolysis bullosa","url":"https://stock-news.laohu8.com/highlight/detail?id=2636738290","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636738290?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:04","pubTimestamp":1779105859,"startTime":"0","endTime":"0","summary":"Krystal Biotech secured UK MHRA marketing authorization for VYJUVEK to treat wounds in dystrophic epidermolysis bullosa patients with COL7A1 mutations from birth.The clearance includes flexible dosing options, including home administration by patients or caregivers.UK launch timing hinges on completion of reimbursement procedures.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL1QNl4k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","IE00BGHQF748.EUR","KRYS","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU0314104364.USD","SG9999014013.SGD","SG9999014021.USD","IE00B64PRP62.GBP","BK4139","IE00BN0W2V16.EUR","SG9999014039.USD","NDAQ","LU2095319765.USD","SG9999014005.SGD","LU2210149790.SGD","BK4112","IE00BN0W2T93.GBP","LU2210150020.SGD","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636078493","title":"Krystal Biotech Announces United Kingdom Mhra Approval of Vyjuvek® for the Treatment of Dystrophic Epidermolysis Bullosa","url":"https://stock-news.laohu8.com/highlight/detail?id=2636078493","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636078493?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:00","pubTimestamp":1779105600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA9Q7MC1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636307338","title":"Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa","url":"https://stock-news.laohu8.com/highlight/detail?id=2636307338","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636307338?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:00","pubTimestamp":1779105600,"startTime":"0","endTime":"0","summary":"VYJUVEK approved for the treatment of DEB from birth with flexible administration options similar to those already granted in the United States, European Union, and Japan VYJUVEK is the first genetic ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/18/3296569/0/en/Krystal-Biotech-Announces-United-Kingdom-MHRA-Approval-of-VYJUVEK-for-the-Treatment-of-Dystrophic-Epidermolysis-Bullosa.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KRYS","UBCP","BK4581","BK4211","BK4588","XBI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636078262","title":"The Bull Case For Krystal Biotech (KRYS) Could Change Following UK Vyjuvek Approval And Rising Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=2636078262","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636078262?lang=en_us&edition=fundamental","pubTime":"2026-05-18 19:29","pubTimestamp":1779103772,"startTime":"0","endTime":"0","summary":"In May 2026, Krystal Biotech received Medicines and Healthcare products Regulatory Agency approval in the UK for Vyjuvek, its gene therapy for dystrophic epidermolysis bullosa, and also reported first-quarter 2026 net income of US$55.93 million with higher earnings per share than a year earlier.\nThis combination of new market access for Vyjuvek and rising profitability strengthens Krystal Biotech’s position in rare genetic disease treatments and adds a fresh dimension to its growth...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/the-bull-case-for-krystal-biotech-krys-could-change-followin-3","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/the-bull-case-for-krystal-biotech-krys-could-change-followin-3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","KRYS","BK4139","BK4588","BK4581","XBI"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.krystalbio.com","stockEarnings":[{"period":"1week","weight":0.0689},{"period":"1month","weight":0.2465},{"period":"3month","weight":0.424},{"period":"6month","weight":0.5049},{"period":"1year","weight":1.673},{"period":"ytd","weight":0.5072}],"compareEarnings":[{"period":"1week","weight":0.0171},{"period":"1month","weight":-0.0168},{"period":"3month","weight":0.1371},{"period":"6month","weight":0.0916},{"period":"1year","weight":0.2074},{"period":"ytd","weight":0.0936}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.012037},{"month":2,"riseRate":0.666667,"avgChangeRate":0.08189},{"month":3,"riseRate":0.555556,"avgChangeRate":0.037905},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.016835},{"month":5,"riseRate":0.555556,"avgChangeRate":0.031146},{"month":6,"riseRate":0.777778,"avgChangeRate":0.125274},{"month":7,"riseRate":0.666667,"avgChangeRate":0.06823},{"month":8,"riseRate":0.125,"avgChangeRate":-0.010983},{"month":9,"riseRate":0.25,"avgChangeRate":-0.037914},{"month":10,"riseRate":0.555556,"avgChangeRate":0.053086},{"month":11,"riseRate":0.888889,"avgChangeRate":0.190014},{"month":12,"riseRate":0.555556,"avgChangeRate":-0.011676}],"exchange":"NASDAQ","name":"Krystal Biotech Inc.","nameEN":"Krystal Biotech Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Krystal Biotech Inc.(KRYS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Krystal Biotech Inc.(KRYS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Krystal Biotech Inc.,KRYS,Krystal Biotech Inc.股票,Krystal Biotech Inc.股票老虎,Krystal Biotech Inc.股票老虎国际,Krystal Biotech Inc.行情,Krystal Biotech Inc.股票行情,Krystal Biotech Inc.股价,Krystal Biotech Inc.股市,Krystal Biotech Inc.股票价格,Krystal Biotech Inc.股票交易,Krystal Biotech Inc.股票购买,Krystal Biotech Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Krystal Biotech Inc.(KRYS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Krystal Biotech Inc.(KRYS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}